Insider Trading Alert - CFN, PACW, JNPR, PHM And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 2, 2013, 167 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $696.00 to $31,440,000.00.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Gallahue Kieran who is Chairman and CEO at CareFusion sold 25,000 shares at $40.09 on Dec. 2, 2013. Following this transaction, the Chairman and CEO owned 147,873 shares meaning that the stake was reduced by 14.46% with the 25,000-share transaction.

Leonard Thomas J who is President, Medical Systems at CareFusion sold 1,250 shares at $39.99 on Dec. 2, 2013. Following this transaction, the President, Medical Systems owned 61,049 shares meaning that the stake was reduced by 2.01% with the 1,250-share transaction.

The shares most recently traded at $39.37, down $0.62, or 1.57% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 4-Week # shares sold: 1,250
  • 12-Week # shares sold: 2,500
  • 24-Week # shares sold: 64,550

The average volume for CareFusion has been 1.5 million shares per day over the past 30 days. CareFusion has a market cap of $8.4 billion and is part of the health care sector and health services industry. Shares are up 39.43% year-to-date as of the close of trading on Monday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 23.3. Currently there are 5 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PacWest Bancorp (PACW) - FREE Research Report

Wagner Matthew P who is Ceo at PacWest Bancorp bought 2,415 shares at $41.30 on Dec. 2, 2013. Following this transaction, the Ceo owned 39,378 shares meaning that the stake was reduced by 6.53% with the 2,415-share transaction.

The shares most recently traded at $40.52, down $0.78, or 1.92% since the insider transaction. Historical insider transactions for PacWest Bancorp go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 10,000

The average volume for PacWest Bancorp has been 579,600 shares per day over the past 30 days. PacWest Bancorp has a market cap of $1.8 billion and is part of the financial sector and banking industry. Shares are up 66.09% year-to-date as of the close of trading on Monday.

PacWest Bancorp operates as the bank holding company for Pacific Western Bank that provides commercial banking products and services to small to medium sized businesses, and the owners and employees of those businesses primarily in Southern California. The stock currently has a dividend yield of 2.43%. The company has a P/E ratio of 26.2. Currently there are 5 analysts that rate PacWest Bancorp a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PACW - FREE

TheStreet Quant Ratings rates PacWest Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, compelling growth in net income, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full PacWest Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Juniper Networks (JNPR) - FREE Research Report

Stensrud William who is Director at Juniper Networks sold 10,000 shares at $20.38 on Dec. 2, 2013. Following this transaction, the Director owned 301,867 shares meaning that the stake was reduced by 3.21% with the 10,000-share transaction.

Elliott Geraldine who is EVP Sales, Services & Support at Juniper Networks sold 39,000 shares at $20.27 on Dec. 2, 2013. Following this transaction, the EVP Sales, Services & Support owned 107,979 shares meaning that the stake was reduced by 26.53% with the 39,000-share transaction.

The shares most recently traded at $20.24, down $0.03, or 0.15% since the insider transaction. Historical insider transactions for Juniper Networks go as follows:

  • 4-Week # shares sold: 46,000
  • 12-Week # shares sold: 46,000
  • 24-Week # shares sold: 46,000

The average volume for Juniper Networks has been 6.5 million shares per day over the past 30 days. Juniper Networks has a market cap of $10.2 billion and is part of the technology sector and computer hardware industry. Shares are up 3.05% year-to-date as of the close of trading on Monday.

Juniper Networks, Inc. designs, develops, and sells products and services that provide network infrastructure for networking requirements of service providers, enterprises, governments, and research and public sector organizations worldwide. The company has a P/E ratio of 27.4. Currently there are 7 analysts that rate Juniper Networks a buy, 1 analyst rates it a sell, and 14 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JNPR - FREE

TheStreet Quant Ratings rates Juniper Networks as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Get the full Juniper Networks Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PulteGroup (PHM) - FREE Research Report

Chadwick John James who is Area President at PulteGroup sold 10,000 shares at $18.69 on Dec. 2, 2013. Following this transaction, the Area President owned 198,580 shares meaning that the stake was reduced by 4.79% with the 10,000-share transaction.

The shares most recently traded at $18.40, down $0.29, or 1.58% since the insider transaction. Historical insider transactions for PulteGroup go as follows:

  • 24-Week # shares bought: 29,140

The average volume for PulteGroup has been 9.3 million shares per day over the past 30 days. PulteGroup has a market cap of $7.2 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 3.3% year-to-date as of the close of trading on Monday.

PulteGroup, Inc., through its subsidiaries, engages in homebuilding and financial services businesses primarily in the United States. The stock currently has a dividend yield of 1.07%. The company has a P/E ratio of 3.0. Currently there are 5 analysts that rate PulteGroup a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PHM - FREE

TheStreet Quant Ratings rates PulteGroup as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full PulteGroup Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 6,000 shares at $10.53 on Dec. 2, 2013. Following this transaction, the CEO & Chairman owned 137.2 million shares meaning that the stake was reduced by 0% with the 6,000-share transaction.

The shares most recently traded at $10.31, down $0.22, or 2.12% since the insider transaction.

The average volume for Opko Health has been 5.0 million shares per day over the past 30 days. Opko Health has a market cap of $4.3 billion and is part of the health care sector and health services industry. Shares are up 119.13% year-to-date as of the close of trading on Monday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China